Cardiac benefits of mineralocorticoid receptor blocking after preeclampsia
Official title: Cardiac Effects of Mineralocorticoid Receptor Antagonism after Preeclampsia (CARDAMOM)
Funded at Massachusetts General Hospital · NIH-11395171 · Data updated 2026-11-12
This study tests whether blocking mineralocorticoid receptors can improve heart blood vessel function and heart remodeling in women who had preeclampsia and later developed high blood pressure.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | August 18, 2025 |
| Project end | May 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $671,741 |
| NIH project number | 5R01HL181150-02 |
| Project ID | NIH-11395171 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adult women with a history of preeclampsia who later develop chronic hypertension may be eligible.
✕Less likely to help
If a participant does not have chronic hypertension or a history of preeclampsia, they may not derive direct benefit.
What this research studies
Women who had preeclampsia are at higher risk for future heart disease. The researchers propose to test a medication that blocks mineralocorticoid receptors to see if it improves how the heart’s small vessels work and how the heart remodels, even if blood pressure doesn’t change much. The project will follow women with prior preeclampsia and chronic hypertension to assess cardiac function, vascular health, and related risk factors, using clinical visits and imaging. This work builds on lab findings and aims to translate them into strategies that could lower future cardiovascular risk for patients like these.
Why it matters
Potential benefit: If successful, the approach could reduce long-term heart disease risk for women who experienced preeclampsia.
How similar studies have gone: Previous work suggests mineralocorticoid receptor signaling affects cardiovascular health, but this exact post-preeclampsia context is being tested.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Honigberg, Michael — Massachusetts General Hospital
- Study coordinator: Honigberg, Michael
Related research
Other NIH-funded projects on the same topics.
-
Ethical, multimodal AI for predicting preeclampsia risk in early pregnancy
A data-driven AI tool uses early-pregnancy information from medical records, ultrasound, and notes to predict preeclampsia risk and support safer pregnancy care.
-
Placental support cells and fetal red blood cell quality in preeclampsia
This grant studies how placental support cells in preeclampsia affect the development and quality of a baby’s red blood cells.
-
Epigenetic clues to preeclampsia in pregnancy
This grant explores how epigenetic changes and paternal factors may contribute to preeclampsia, a condition that can affect pregnancy health.
-
Environmental air pollutants linked to preeclampsia risk in pregnancy
This study looks at whether common air pollutants called PAHs increase the risk of preeclampsia during pregnancy.
-
Dynamic risk prediction and subtyping of hypertensive disorders in pregnancy
A digital health approach uses AI to spot early warning signs of preeclampsia and gestational hypertension from pregnancy data, so clinicians can tailor care for pregnant people.
-
Folate Receptor Beta and its Role in Preeclampsia
This study explores how a protein called folate receptor beta on placental immune cells may drive or worsen preeclampsia in pregnancy, with hopes of finding new ways to prevent or treat the condition.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.